Premium
R‐GDP SCHEDULE IN PATIENTS WITH REFRACTORY OR RELAPSED B‐CELL NON‐HODGKIN LYMPHOMA (B‐NHL)
Author(s) -
Rovira J,
GonzálezBarca E,
M. Sancho J,
Kelleher N,
Rodríguez M,
Fox L,
Parody R,
Martin S,
Vicent A,
Villarroel J,
de la Fuente C,
Ribera J. M,
Sureda A,
Escoda L
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.42_2881
Subject(s) - medicine , rituximab , lymphoma , gastroenterology , gemcitabine , salvage therapy , toxicity , refractory (planetary science) , autologous stem cell transplantation , neutropenia , surgery , chemotherapy , astrobiology , physics